A selective antagonist of mineralocorticoid receptor eplerenone in cardiology practice

被引：0
|
作者：
Gegenava, B. B. [1 ]
Drapkina, O. M. [1 ]
机构：
[1] IM Sechenov First Moscow State Med Univ, Moscow 119991, Russia
来源：
RATIONAL PHARMACOTHERAPY IN CARDIOLOGY | 2015年 / 11卷 / 02期
关键词：
aldosterone; heart failure; atrial fibrillation; chronic renal failure; albuminuria; eplerenone; spironolactone; gynecomastia;
D O I：
10.20996/1819-6446-2015-11-2-177-181
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The role of aldosterone in pathophysiological processes is considered. The effects of the selective antagonist of mineralocorticoid receptor eplerenone are analyzed. The advantages of eplerenone compared with spironolactone are discussed.
引用
收藏
页码：177 / 181
页数：5
相关论文
共 50 条
  • [41] Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor
    Rogerson, FM
    Yao, YH
    Smith, BJ
    Fuller, PJ
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2004, 31 (10): : 704 - 709
  • [42] Is esaxerenone the ultimate mineralocorticoid receptor antagonist?
    Satoshi Hoshide
    Hypertension Research, 2023, 46 : 516 - 517
  • [43] Mineralocorticoid Receptor Antagonist for Renal Protection
    Ma, Terry King-Wing
    Szeto, Cheuk-Chun
    RENAL FAILURE, 2012, 34 (06) : 810 - 817
  • [44] Mineralocorticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases
    Bauersachs, Johann
    Jaisser, Frederic
    Toto, Robert
    HYPERTENSION, 2015, 65 (02) : 257 - U42
  • [45] Eplerenone, a selective mineralocorticoid receptor antagonist, inhibits cyclic stretch-induced NADPH activation through Nox1 in rat aortic smooth muscle cells
    Miwa, Y
    Ohmine, T
    Sasaguri, T
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2006, 100 : 74P - 74P
  • [46] Eplerenone, a selective aldosterone receptor antagonist, inhibits atherosclerosis in apolipoprotein E-deficient mice
    Suzuki, J
    Iwai, M
    Li, Z
    Cui, TX
    Ide, A
    Okamoto, S
    Shigematsu, Y
    Higaki, J
    Horiuchi, M
    JOURNAL OF HYPERTENSION, 2004, 22 : S163 - S163
  • [47] The selective aldosterone receptor antagonist eplerenone ameliorates angiotensin II-induced endorgan damage
    Fiebeler, A
    Mazak, I
    Muller, DN
    Shagdarsuren, S
    Lindschau, C
    Dechend, R
    Pilz, B
    Luft, FC
    EUROPEAN HEART JOURNAL, 2003, 24 : 220 - 220
  • [48] Mineralocorticoid receptor antagonist therapy in patients with ischemic heart failure and ventricular tachycardia: a comparative analysis of spironolactone vs. eplerenone
    Szakal, I
    Komlosi, F.
    Toth, P.
    Vamosi, P.
    Arnoth, B.
    Bohus, G. Y.
    Szegedi, N.
    Sallo, Z.
    Perge, P.
    Osztheimer, I
    Merkely, B.
    Geller, L.
    Nagy, K., V
    EUROPEAN HEART JOURNAL, 2024, 45
  • [49] Mineralocorticoid receptor antagonist therapy in patients with ischemic heart failure and ventricular tachycardia: a comparative analysis of spironolactone vs. eplerenone
    Szakal, I
    Komlosi, F.
    Toth, P.
    Vamosi, P.
    Arnoth, B.
    Bohus, G. Y.
    Szegedi, N.
    Sallo, Z.
    Perge, P.
    Osztheimer, I
    Merkely, B.
    Geller, L.
    Nagy, K., V
    EUROPEAN HEART JOURNAL, 2024, 45
  • [50] Predictive factors of selective mineralocorticoid receptor antagonist treatment in chronic central serous chorioretinopathy
    Róbert Gergely
    Illés Kovács
    Zsuzsanna Récsán
    Gábor László Sándor
    Cecília Czakó
    Zoltán Zsolt Nagy
    Mónika Ecsedy
    Scientific Reports, 10
12345